The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPPIX.L Regulatory News (PPIX)

  • There is currently no data for PPIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Annual Financial Report

25 Mar 2014 07:00

RNS Number : 0583D
ProPhotonix Limited
25 March 2014
 

 

ProPhotonix Limited

 ("ProPhotonix" or "the Company")

 

PRELIMINARY RESULTS FOR THE YEAR ENDED DECEMBER 31, 2013

 

ProPhotonix Limited (London Stock Exchange - AIM: PPIX and PPIR, OTC: STKR), a designer and manufacturer of LED illumination systems and laser diode modules with operations in Ireland and the United Kingdom, today announces its unaudited preliminary results for the year ended December 31, 2013.

 

Annual General Meeting

The Company will hold the Annual General Meeting of the Shareholders on May 22, 2014 at

10:00 AM London Summer Time at the offices of K&L Gates LLP, One New Change, London

EC4M 9AF. The Record date is set at April 7, 2014 for all shareholders of record.

 

Financial Highlights

· Revenue increased 12% to $15.6 million

· Gross profit increased 38.6% to $6.0 million

· Gross profit margin improved to 38.3%

· Operating loss declined 62% to $1.2 million(1)  

· EBITDA loss declined 73.8% to $0.7 million(1)  

· Order bookings increased 17% to $17.6 million

· Backlog at December 31, 2013 of $6.9 million grew 31%

· Percentage revenue by market sectors: industrial 79%, medical 16%, and homeland security & defense 5%

· Percentage revenue by geography: 52% Europe, 31% North America and 17% Rest of World

· On June 20, 2013, the Company secured new loan financing with net availability of $2.5 million through an existing lender to the Company alongside a new lender.

· On November 29, 2013, the Company entered into an amendment to an existing revolving credit facility with Barclays Bank to increase the existing credit facility from £650,000 ($1.1 million) to £1,400,000 ($2.3 million) and extending the duration through the minimum of November 30, 2015.

· Available borrowing capacity of $1.8 million from its loan facilities at December 31, 2013

(1) Includes $582,000 non-recurring charges

 

Tim Losik, President & CEO, Commented:

 

"During 2013 the Company experienced an improvement in business activity with order bookings increasing 17% and the December 31, 2013 backlog up 31% from December 31, 2012; ending 2013 with a book-to-bill ratio of 1.13 (2012:1.08). Of particular note are the 69% increase in bookings and 40% growth in revenue for the Americas region which has been a significant regional growth focus. New customer activity is a cornerstone for our growth and I am pleased that we are continuously partnering with new customers. Revenue from new customers accounted for $1.5 million of total revenue growth across several market sectors, including: 3D Scanning for 3D printing, Warehouse Robotics, Transport Container Monitoring and Inspection, Medical Devices, UV curing, Aeronautics, and Industrial Automation and Inspection.

 

"The revenue increase and cost reductions resulted in dramatic improvement in operating performance and results. During the second half of 2013, we realized significant improvement in operating performance versus the first half 2013. Comparative improvements in the second half 2013 versus first half 2013 (excluding the restructuring and one-time charges of $582K in the first half) include: Operating loss decreased 84% narrowing from ($517,000) to ($82,000) and EBITDA improved 164% from a loss of ($275,000) to a positive EBITDA of $177,000. However, these improvements were somewhat offset by non-cash changes in foreign currency exchange rates and the resulting increase in material purchase prices, and shifts in product mix; thereby depressing second half gross profit. The improvements in second half operating income and EBITDA are primarily the result of reductions in general and administrative costs. We always seek to mitigate the effects of shifts in the revenue mix, but predicting and controlling this can be difficult."

 

 

Full Year 2013 Financial Results

 

Revenue for the year ended December 31, 2013 was $15.6 million, an increase of 12% compared with $13.9 million in 2012. Gross profit was $6.0 million compared to $4.3 million in 2012. Gross profit margin increased to 38.3% from 31.0% in 2012 due to a shift in product mix and an increase in volume.

 

Operating expenses, excluding intangible amortization charges, totaled $7.0 million versus $7.3 million in 2012. Sales and marketing expenses decreased 12% in 2013 over 2012, while general and administrative and research and development expenses were approximately flat over the same period and include restructuring and one-time charges of $0.6 million taken in the first half of 2013. The operating loss was $1.2 million, as compared to a $3.1 million loss in 2012 and EBITDA was a loss of $0.7 million versus a loss of $2.6 million in 2012. Net loss was $1.2 million compared to the 2012 net loss of $2.9 million. Included in the operating expenses, operating loss and EBITDA is approximately $0.6 million of restructuring and one-time charges.

 

Strategy and Markets

 

ProPhotonix consists of two business units: an LED systems manufacturing business based in Ireland (Cork), and a laser modules production and laser diode distribution business located in the United Kingdom (Hatfield Broad Oak). Corporate headquarters and the North American sales activities are based in Salem, New Hampshire, USA. The fundamental strategy of the Company is growth in revenue through its existing customers, new customer activity, and new product and market expansion. ProPhotonix's short-term strategy is to reach sustained positive EBITDA, cash flow, and net income as soon as possible. These goals will be accomplished through a relentless focus on cost management and most importantly through revenue growth.

 

ProPhotonix growth in the medium-term will be accomplished with new customer wins with the conversion of development orders into longer run orders, and also through expansion into new markets and with new products. In addition to the few important areas where we are currently focused, we will continuously evaluate additional high growth opportunities by geography and business line. 

ProPhotonix sells its products principally into three markets: industrial (primarily machine vision illumination), medical, and homeland security and defense. The Company foresees growth opportunities in all three markets it serves which are briefly described below:

 

Industrial (Machine Vision)

Within the industrial market, machine vision is the term used to describe computerized analysis for controlling manufacturing processes, for example automated inspection. In terms of quality and speed, lighting is often a critical component in machine vision and the Company manufactures both LED systems and lasers designed specifically for this market. The recently enhanced 3D Pro Laser line generators and improved LED line light family specifically address this market.  

Medical

 

The Company has experienced successes in the medical (including dental) market and has gained a foothold in the market, supplying a variety of applications, with current customers including the world leader in stationary imaging equipment, a portable x-ray equipment manufacturer, a dental imaging manufacturer and also a pioneer in the manufacturing of devices offering eye tracking capability utilizing ProPhotonix's custom infrared LED arrays. The Company intends to broaden its product marketing effort in the medical field since it offers significant long-term revenue growth opportunities.

Homeland Security & Defense 

LED systems, laser modules and laser diodes are used in a wide variety of applications in the security and defense fields. The Company currently supplies several defense sighting manufacturers in the US and Europe, as well as leading manufacturers of Auto Number Plate Recognition systems. This market offers significant growth opportunities for ProPhotonix over the next several years and the Company is currently marketing its laser and LED capabilities to additional security and optical character recognition systems companies in this market space.

 

Outlook

 

ProPhotonix begins 2014 with the strongest ever backlog at our business units and with the necessary funding in place to move forward in 2014. Included in 2013 bookings are about $800,000 of customer bookings relating to new customer projects (non-recurring engineering development), of which approximately $700,000 will be recognized revenue in 2014. We expect to begin shipping trial and production orders resulting from these projects during 2014 and thereafter. These potential high volume OEM (custom) applications include illuminators for the semiconductor, optical sorting, endoscopy, and vascular imaging markets. We look forward to another year of progress in 2014 and expect that first half revenue will be in the range of $7.8 and $8.2 million.

 

 

 

 

 

Enquiries:

 

ProPhotonix Limited

Tim Losik, President and CEO

 

Tel: +1 603 870 8220

ir@prophotonix.com

N+1 Singer

Andrew Craig/ Ben Wright

Tel: +44 (0) 207 496 3000

Nominated Adviser and Broker

 

 

 

 

About ProPhotonix

 

ProPhotonix Limited, headquartered in Salem, New Hampshire, is an independent designer and manufacturer of diode-based laser modules and LED systems for industry leading OEMs and medical equipment companies. In addition, the Company distributes premium diodes for Oclaro, Osram, QSI, Panasonic, and Sony. The Company serves a wide range of markets including the machine vision, industrial inspection, security, and medical markets. ProPhotonix has offices and subsidiaries in the U.S., Ireland, U.K., and Europe. For more information about ProPhotonix and its innovative products, visit the Company's web site at www.prophotonix.com.

 

 

 

ProPhotonix Limited

Consolidated Statements of Operations and Comprehensive (Loss)

($ in thousands except share and per share data)

(unaudited)

 

Years Ended

December 31,

2013

2012

Net Revenue

$ 15,599

$ 13,904

Cost of Revenue

(9,628)

(9,597)

Gross Profit

5,971

4,307

Research & Development Expenses

(941)

(922)

Selling, General & Administrative Expenses

(6,091)

(6,403)

Amortization of Intangible Assets

(120)

(118)

Operating Loss

(1,181)

(3,136)

Other Income / (Expense), net

295

490

Warrant and Debt Acquisition expense

(103)

-

Interest Expense

(237)

(257)

Loss Before Taxes

(1,226)

(2,903)

Tax Benefit

73

-

Net Loss

$ ( 1,153)

$ ( 2,903)

Other comprehensive income (loss):

Foreign currency translation

(368)

(199)

Total comprehensive loss

$ ( 1,521)

$ ( 3,102)

Loss Per Share:

Basic and diluted net loss per share

($0.01)

($0.04)

Basic and diluted weighted average shares outstanding

80,496,977

76,059,457

 

 

 

PROPHOTONIX LIMITED

 CONSOLIDATED BALANCE SHEETS

(unaudited)

 ($ in thousands except share and per share data)

 

December 31

 

2013

 

2012

 

Assets

Current assets:

Cash and cash equivalents

$ 402

$ 1,278

Accounts receivable, less allowances of $19 in 2013 and $31 in 2012

2,559

2,225

Inventories

2,003

2,033

Prepaid expenses and other current assets

220

234

 

 

Total current assets

5,184

5,770

Net property, plant and equipment

303

523

Goodwill

486

467

Acquired intangible assets, net

102

218

Other long-term assets

354

23

 

 

Total assets

$ 6,429

$ 7,001

 

 

Liabilities and Stockholders' Equity (Deficit)

Current liabilities:

Revolving credit facility

$ 1,127

$ 662

Current portion of long-term debt

265

2,387

Capital lease obligations

10

10

Accounts payable

1,542

2,000

Income taxes payable

-

-

Accrued expenses

1,296

1,084

 

 

Total current liabilities

4,240

6,143

Long-term debt, net of current portion

2,445

-

Long-term portion of capital lease obligations

-

10

Other long-term liabilities

178

178

 

 

Total liabilities

6,863

6,331

 

 

Stockholders' equity (deficit):

Common stock, par value $0.001; shares authorized 150,000,000 at December 31, 2013 and at December 31, 2012; 83,665,402 shares issued and outstanding at December 31, 2013 and 76,059,457 at December 31, 20127

84

76

Additional paid-in capital

111,302

110,893

Accumulated deficit

(111,674 )

(110,521 )

Accumulated other comprehensive income

(146)

222

 

 

Total stockholders' equity (deficit)

(434)

670

 

 

Total liabilities and stockholders' equity

$ 6,429

$ 7,001

 

 

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF CASH FLOWS

In thousands

(unaudited)

 

Years Ended December 31

 

2013

 

2012

 

Operations

Net loss

$ (1,153)

$ (2,903)

Adjustments to reconcile net loss to net cash used in operating activities:

Stock-based compensation expense

169

143

Depreciation and amortization

332

396

Foreign exchange (gain) loss

(408)

(188)

Amortization of debt discount and financing costs

96

-

Loss on disposal of assets

(7)

-

Provision for inventories

120

75

Provision for bad debts

(12)

25

Other change in assets and liabilities:

Accounts receivable

(222)

199

Inventories

(8)

(372)

Prepaid expenses and other current assets

20

57

Accounts payable

(518)

505

Accrued expenses

171

261

Other assets and liabilities

(9)

20

 

 

Net cash used in operating activities

(1,429 )

(1,782 )

 

 

Investing

Purchase of property, plant and equipment

(17 )

(67 )

 

 

Net cash used in investing activities

(17 )

(67 )

 

 

Financing

Borrowings of revolving credit facilities, net

438

-

Proceeds from issuance of long-term debt

800

-

Principal repayment of long-term debt

(339 )

(889 )

Debt issuance costs

(398 )

-

 

 

Net cash provided by (used in) financing activities

501

(889)

 

 

Effect of exchange rate on cash

69

(50)

 

 

Net change in cash and equivalents

(876)

(2,788)

Cash and equivalents at beginning of year

1,278

4,066

 

 

Cash and equivalents at end of period

$ 402

$ 1,278

 

 

Supplemental cash flow information:

Cash paid for interest

$ 263

$ 228

Common stock issued in connection with financing

$ 193

$ -

Warrants issued in connection with financing

$ 55

$ -

 

 

 

 

 

 

 

 

 

 

 

PROPHOTONIX LIMITED

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY / (DEFICIT)

(in thousands)

 

 

Common Stock

 

Additional Paid inCapital

 

AccumulatedDeficit

 

Accumulated Other ComprehensiveIncome

 

TotalStockholders'Equity (Deficit)

 

 

Shares

 

Par$0.001

 

 

 

Balance December 31, 2011 ...........................

76,059

$ 76

$ 110,751

$ (107,618)

$ 421

$ 3,630

 

Share based compensation, net of forfeitures ..................

-

-

143

-

-

143

 

Translation adjustment .....

-

-

-

-

(199)

(199)

 

Net loss ............................

-

-

-

(2,903)

-

(2,903)

 

 

 

 

 

 

 

 

 

 

Balance December 31, 2012 ...........................

76,059

$ 76

$ 110,893

$ (110,521)

$ 222

$ 670

 

 

 

 

 

 

 

 

Share based compensation, net of forfeitures ..................

-

-

169

-

-

169

 

Issuance of common stock to settle liabilities ........

7,606

8

185

-

-

193

 

Issuance of warrants for financings ...................

-

-

55

-

-

55

 

Translation adjustment....

(368)

(368)

 

Net loss ............................

-

-

-

(1,153)

-

(1,153)

 

 

 

 

 

 

 

 

 

Balance December 31, 2013 ...........................

83,665

$ 84

$ 111,302

$ (111,674)

$ (146)

$ (434)

 

 

 

 

 

 

 

 

Values may not add due to rounding

 

 

Notes to unaudited Preliminary Results

Basis of Presentation

The financial information set out in this document does not constitute the Company's statutory accounts for 2012 and 2013 or the Company's annual audited accounts for 2013 to be published and sent to its shareholders in accordance with Rule 19 of the AIM Rules for Companies. The 2013 accounts included herein are unaudited and therefore subject to change at the time the audited accounts are issued. The 2013 unaudited preliminary financial statements were prepared under US GAAP and were approved on March 24, 2014, by the Directors for issue on March 25, 2014. It is intended that the Company's 2013 annual report and audited accounts will be available to shareholders on or about April 25, 2014.

 

Cautionary Statement

 

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than statements of historical fact, including without limitation, those with respect to ProPhotonix's goals, plans and strategies set forth herein are forward-looking statements. The following important factors and uncertainties, among others, could cause actual results to differ materially from those described in these forward-looking statements: uncertainty that cash balances may not be sufficient to allow ProPhotonix to meet all of its business goals; uncertainty that ProPhotonix's new products will gain market acceptance; the risk that delays and unanticipated expenses in developing new products could delay the commercial release of those products and affect revenue estimates; the risk that one of our competitors could develop and bring to market a technology that is superior to those products that we are currently developing; and ProPhotonix's ability to capitalize on its significant research and development efforts by successfully marketing those products that the Company develops. Forward-looking statements represent management's current expectations and are inherently uncertain. All Company, brand, and product names are trademarks or registered trademarks of their respective holders. ProPhotonix undertakes no duty to update any of these forward-looking statements.

 

Use of Non-GAAP Financial Measures

 

The Company provides non-GAAP financial measures, such as EBITDA, to complement its consolidated financial statements presented in accordance with GAAP. Non-GAAP financial measures do not have any standardized definition and, therefore, are unlikely to be comparable to similar measures presented by other reporting companies. These non-GAAP financial measures are intended to supplement the user's overall understanding of the Company's current financial and operating performance and its prospects for the future. Specifically, the Company believes the non-GAAP results provide useful information to both management and investors by identifying certain expenses, gains and losses that, when excluded from the GAAP results, may provide additional understanding of the Company's core operating results or business performance, which management uses to evaluate financial performance for purposes of planning for future periods. However, these non-GAAP financial measures are not intended to supersede or replace the Company's GAAP results.

 

The Company uses EBITDA (earnings before interest, taxes, depreciation, amortization, and stock-based compensation) as a non-GAAP financial measure in this press release. A reconciliation of net loss to EBITDA for the total year 2013 and 2012 is as follows:

 

 

(in thousands)

Year Ended December 31,

2013

2012

Net Loss

(1,153)

(2,903)

Plus:

Interest and other expense / (income), net

45

(233)

Depreciation

212

278

Intangible asset amortization

120

118

Stock based compensation

169

143

Taxes

(73)

-

EBITDA Loss

(680)

(2,597)

Restructuring and nonrecurring charges

582

-

Adjusted EBITDA loss

(98)

(2,597)

 

 

 

 

########

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FR QKQDKCBKDDNB
Date   Source Headline
16th Dec 20217:00 amRNSSale of ProPhotonix and cancelation of AIM Listing
17th Nov 20217:00 amRNSNotice of GM
11th Nov 202111:05 amRNSSecond Price Monitoring Extn
11th Nov 202111:00 amRNSPrice Monitoring Extension
11th Nov 20217:00 amRNSProPhotonix Announces Merger Agreement
2nd Nov 20217:00 amRNSProPhotonix Extends COBRA HyperSpec range
14th Sep 20217:00 amRNSProPhotonix announces the new UV COBRA Cure FX4
8th Sep 20217:00 amRNS2021 Half-year Report
9th Jun 20217:00 amRNSPosting of Annual Report and Accounts
2nd Jun 20217:00 amRNSNew Wavelengths added to UVC LED System
25th Mar 20217:00 amRNSResults for the year ended December 31, 2020
26th Jan 20217:00 amRNSNew Hyperspectral COBRA MultiSpec LED Line Light
16th Nov 20202:05 pmRNSSecond Price Monitoring Extn
16th Nov 20202:00 pmRNSPrice Monitoring Extension
12th Nov 20207:00 amRNSAdmission of Shares
10th Nov 20207:00 amRNSProPhotonix introduces 265nm UVC LED Lamp
9th Nov 20204:45 pmRNSResult of AGM and Director / PDMR Shareholdings
9th Oct 20207:00 amRNSPOSTING OF NOTICE OF ANNUAL GENERAL MEETING
8th Oct 20207:00 amRNSNew RGB-IR & RGB-White COBRA MultiSpec Line Lights
7th Oct 20203:07 pmRNSHolding(s) in Company
10th Sep 20207:00 amRNSINTERIM RESULTS FOR HALF YEAR ENDED JUNE 30, 2020
3rd Sep 20204:40 pmRNSSecond Price Monitoring Extn
3rd Sep 20204:35 pmRNSPrice Monitoring Extension
3rd Sep 20202:05 pmRNSSecond Price Monitoring Extn
3rd Sep 20202:00 pmRNSPrice Monitoring Extension
2nd Sep 20207:00 amRNSPROdigii Digital Lasers Range - 5 New Wavelengths
27th Aug 20207:00 amRNSRESULTS FOR THE YEAR ENDED DECEMBER 31, 2019
25th Aug 20201:47 pmRNSNOTICE OF EXTENSION OF RIGHTS PLAN
24th Jul 20207:00 amRNSHolding(s) in Company
16th Jul 20207:00 amRNSChange of Adviser and Director Disclosures
29th Jun 20207:00 amRNSCustom LED Backlight wins VSD Innovators Award
23rd Jun 20207:00 amRNSAccounts Reporting Extension & Trading Update
30th Apr 20207:00 amRNSDirectorate Change
9th Apr 20207:00 amRNSCOVID – 19 and Trading Update
19th Mar 20207:00 amRNS3 Year Framework Product Supply & IP Agreement
16th Mar 20207:00 amRNSProPhotonix - UV LED Water Disinfection
16th Jan 20207:00 amRNSTrading Update 2019
26th Nov 20197:00 amRNSHolding(s) in Company
10th Oct 20197:00 amRNS5-Year Master Purchase Agreement - Fortune 50 CGLM
12th Sep 20197:00 amRNSProPhotonix to Exhibit UV Lamps at Labelexpo 2019
6th Sep 20197:00 amRNSProPhotonix issues Half-year Report
3rd Sep 20197:00 amRNSNew High-Powered Red Laser Diode from Ushio
31st May 201911:59 amRNSProPhotonix Notification of Major Holdings
31st May 201911:58 amRNSProPhotonix Notification of Major Holdings
24th May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
23rd May 20197:00 amRNSPPIX Issues Director/PDMR Shareholding Notice
17th May 20197:00 amRNSProPhotonix Announces Trading Update
16th May 20195:58 pmRNSPPIX Announces AGM Results and PDMR Shareholdings
16th May 20197:00 amRNSPPIX Offers New COBRA Cure Mini UV Curing System
9th Apr 20197:00 amRNSProPhotonix Honored by Vision Systems Design 2019

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.